TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27146373

Group type: EXPERIMENTAL
Intervention: Daily training for 12 weeks in phoneme/grapheme mapping, reading comprehension, and reading speed (Intervention group, n=47)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Ordinary classroom activities (Control group, n=37)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intervention group (n=47)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Typically developing students (n=66)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Poor readers identified in grade 2 (n=2212)
Number of subjects: 57
Study: 24498399

Group type: EXPERIMENTAL
Intervention: LMWF-5A (4 mL or 10 mL)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Vehicle control (saline)
Number of subjects: 329
Study: 23300745

Group type: EXPERIMENTAL
Intervention: Azacitidine 37.5 mg/sqm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/sqm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard chemotherapy (7+3 cytarabine plus daunorubicin and intermediate-dose cytarabine)
Number of subjects: 12
Study: 20591173

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 200 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 400 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18219959

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 110

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 110
Study: 15802911

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (verum group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study: 11940545

Group type: EXPERIMENTAL
Intervention: Beta-blocker nebivolol 5 mg daily
Number of subjects: 3741
Study: 9588378

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low dose haloperidol
Number of subjects: 48
Study: 8746104

Group type: EXPERIMENTAL
Intervention: Cefatrizine at a dose of 1 g/day for 10 days
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cefpodoxime proxetil at a dose of 400 mg/day for 10 days
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cefatrizine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cefatrizine and Cefpodoxime proxetil
Number of subjects: 250
Study: 2693918

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg i.m. every 3 or 4 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate withdrawal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate therapy
Number of subjects: 22
Study: 322696

Group type: EXPERIMENTAL
Intervention: Intravenous BCG treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Chemotherapy only (DNR/ARAC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BCG treated group
Number of subjects: 81
Study: 31299343

Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor (CGF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (non-CGF)
Number of subjects: 60
Study: 30802689

Group type: EXPERIMENTAL
Intervention: AL 441 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AL 882 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28799128

Group type: COMPARATOR
Intervention: Epidural catheter (group C)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: No epidural catheter (group N)
Number of subjects: 154
Study: 26012779

Group type: EXPERIMENTAL
Intervention: AFXL-assisted PDT with 90 min incubation time
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional PDT with 180 min incubation time
Number of subjects: 46
Study: 25627186

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anterior stromal puncture (ASP)
Number of subjects: 40
Study: 22111821

Group type: EXPERIMENTAL
Intervention: Postdilutional online hemodiafiltration (oHDF)
Number of subjects: 54

Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 54
Study: 19732311

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg or 20 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17713974

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (oral administration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15921803

Group type: EXPERIMENTAL
Intervention: Carvedilol (non-selective beta-blocker)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Metoprolol (selective beta-blocker)
Number of subjects: 22
Study: 11825813

Group type: EXPERIMENTAL
Intervention: Beta irradiation (750 cGy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (inactive applicator)
Number of subjects: 61
Study: 10489259

Group type: EXPERIMENTAL
Intervention: Categorization task with familiar stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition task with familiar stimuli
Number of subjects: 0
Study: 8599282

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 300 mg administered in a 120 min iv infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (identically looking to PTX)
Number of subjects: 25
Study: 2698515

Group type: EXPERIMENTAL
Intervention: 500 mg Cinoxacin b.i.d. for 5 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 37
Study: 1095116

Group type: EXPERIMENTAL
Intervention: Biochemical profile
Number of subjects: 2816
Study: 30967597

Group type: EXPERIMENTAL
Intervention: UGT2B17*2
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CYP19A1 rs10046 AA vs. AG/GG genotypes
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CYP19A1 low estrogen alleles rs10046 G and rs4646 A
Number of subjects: 125
Study: 30611694

Group type: EXPERIMENTAL
Intervention: 1 suture technique
Number of subjects: 37

Group type: COMPARATOR
Intervention: sutureless technique
Number of subjects: 37
Study: 28697504

Group type: EXPERIMENTAL
Intervention: Cooling vest during physical training program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cotton T-shirt during physical training program
Number of subjects: 18
Study: 26531075

Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment (IPT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Minimal caries removal with both resin‐modified glass ionomer base material and luting cement (MCRB/L)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Minimal caries removal with only resin‐modified glass ionomer luting cement (MCRL)
Number of subjects: 96
Study: 23627832

Group type: EXPERIMENTAL
Intervention: DBX (thermogenic dietary supplement containing 340 mg of total caffeine plus green tea extract, yerba mate extract, carnitine tartrate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DBX
Number of subjects: 12
Study: 21628014

Group type: COMPARATOR
Intervention: PillCam SB2
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: MiroCam capsule
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 73
Study: 19702600

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RF-ablation) for AVNRT and WPW syndrome
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: AVNRT
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Episodes of tachycardia more than once a month
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Arrhythmia duration longer than one hour
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Symptoms during activity and at rest
Number of subjects: 176
Study: 16923310

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Glutamine and antioxidant therapy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 1200
Study: 15273211

Group type: EXPERIMENTAL
Intervention: 20% of MVIC
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 60% of MVIC
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 100% MVIC
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 72
Study: 12505808

Group type: EXPERIMENTAL
Intervention: 1% testosterone gel, 10 g/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9856366

Group type: EXPERIMENTAL
Intervention: Captopril at 50 mg twice a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8587096

Group type: EXPERIMENTAL
Intervention: Rheumatology case report forms
Number of subjects: 30

Group type: COMPARATOR
Intervention: Structured instruments from other disciplines
Number of subjects: 30
Study: 1694945

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg twice daily for 13 weeks
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo twice daily for 13 weeks
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study: 41475

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg i.v. dose of labetalol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg i.v. dose of labetalol
Number of subjects: 18
Study: 27997257

Group type: EXPERIMENTAL
Intervention: Carbohydrate bar
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mixed carbohydrate formats
Number of subjects: 12
Study: 25427033

Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5-Hz rTMS and Anodal tDCS
Number of subjects: 10
Study: 23870127

Group type: EXPERIMENTAL
Intervention: Dynein targeting to the cell cortex via Gαi/LGN/NuMA-dependent pathway and 4.1G/R and NuMA-dependent pathway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric plasma membrane elongation in response to spindle mispositioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynein-dependent spindle anchoring at the stationary cell cortex
Number of subjects: 0
Study: 22462237

Group type: EXPERIMENTAL
Intervention: High-frequency electric sparkle and point-injection therapy (HESPT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Warming needle moxibustion
Number of subjects: 205

Group type: COMPARATOR
Intervention: Point-injection therapy
Number of subjects: 205
Study: 19699853

Group type: EXPERIMENTAL
Intervention: SCH 530348 in addition to standard of care
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 10000
Study: 17116522

Group type: EXPERIMENTAL
Intervention: HIV/AIDS educational intervention
Number of subjects: 200
Study: 15146228

Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT) plus dialogue nursing intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quiet time plus dialogue nursing intervention
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both interventions (TT and quiet time)
Number of subjects: 18
Study: 11730179

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 110, 220, 330, and 440 microg, twice daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Flunisolide 500 and 1,000 microg, twice daily
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Oral prednisone 7.5 mg daily
Number of subjects: 153
Study: 9155405

Group type: EXPERIMENTAL
Intervention: Banana flakes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medical treatment for diarrhea
Number of subjects: 31
Study: 7962423

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) imaging in PCOS patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PCOS patients with ovarian thickened tunica
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TVS imaging
Number of subjects: 32
Study: 29775698

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (nonplacement of TachoSil)
Number of subjects: 100
Study: 26797318

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall study experience
Number of subjects: 128
Study: 25003980

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 105
Study: 22613099

Group type: EXPERIMENTAL
Intervention: Omeprazole plus Bethanacol (OB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo/Placebo (PP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Omeprazole/Placebo (OP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bethanacol/Placebo (BP)
Number of subjects: 22
Study: 20436439

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 45
Study: 18954540

Group type: EXPERIMENTAL
Intervention: roller bar mouse
Number of subjects: 15

Group type: COMPARATOR
Intervention: conventional mouse
Number of subjects: 15
Study: 16171291

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12787319

Group type: EXPERIMENTAL
Intervention: Neurotrophins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small molecule mimetics
Number of subjects: 0
Study: 10918646

Group type: EXPERIMENTAL
Intervention: Loop diuretic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intravenous beta blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium channel blockers or magnesium
Number of subjects: 0
Study: 8872727

Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 18
Study: 1640282

Group type: EXPERIMENTAL
Intervention: Hib polysaccharide conjugated to outer membrane protein complex of Neisseria meningitidis (PRP‐OMP)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Hib polysaccharide‐tetanus toxoid conjugate (PRP‐T)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Hib oligomers conjugated to the mutant diphtheria toxin CRM197 (HbOC)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Unconjugated PRP
Number of subjects: 458

Group type: COMPARATOR
Intervention: All three vaccines (PRP‐OMP, PRP‐T, HbOC)
Number of subjects: 458
Study: 6725168

Group type: EXPERIMENTAL
Intervention: Contingency management program ($10.00 for opiate-free urine specimens)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group ($5.00 for providing a specimen twice weekly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contingency management program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 31479116

Group type: EXPERIMENTAL
Intervention: Optimized prehospital management (OPM) based on the Los Angeles Motor Scale (LAMS) with a cut point ≥4
Number of subjects: 116

Group type: COMPARATOR
Intervention: Management in a Mobile Stroke Unit (MSU)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: LAMS at a cut point of 4 or higher
Number of subjects: 116
Study: 29798149

Group type: EXPERIMENTAL
Intervention: Optimized target delineation in IMRT (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine delineation of target areas (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 26880141

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Sticker reminders
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Control group (routine reminder)
Number of subjects: 1116
Study: 24582119

Group type: EXPERIMENTAL
Intervention: fesoterodine (8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tolterodine extended‐release (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 22086749

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 48

Group type: COMPARATOR
Intervention: First Generation Antipsychotics (FGAs) - Haloperidol or Trifluoperazine
Number of subjects: 48
Study: 19464313

Group type: EXPERIMENTAL
Intervention: Cortical processing of T-junctions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retinal processing of T-junctions
Number of subjects: 0
Study: 17412741

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 18325

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 18325
Study: 16334880

Group type: EXPERIMENTAL
Intervention: Videophone assistance (telemedicine group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard home hospitalization care (control group)
Number of subjects: 32
Study: 12190675

Group type: EXPERIMENTAL
Intervention: Coloanal J pouch anastomosis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 64
Study: 9689828

Group type: COMPARATOR
Intervention: GH deficiency (GHD)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Obesity (OB)
Number of subjects: 575
Study: 8092094

Group type: EXPERIMENTAL
Intervention: Moderately protein‐restricted diet (0.8 g.kg body wt‐1.d‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unrestricted protein diet (> 1.6 g.kg body wt‐1.d‐1)
Number of subjects: 22
Study: 2679238

Group type: EXPERIMENTAL
Intervention: Cimetidine 7.5 mg/kg (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ranitidine 1.5 mg/kg (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ranitidine 2.0 mg/kg (group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 60
Study: 1189983

Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K1 (Konakion) administered intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (Marevan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K1 (Konakion)
Number of subjects: 0
Study: 28414496

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Digit Symbol Substitution Test (DSST)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trail-Making Test
Number of subjects: 16
Study: 25675062

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Successful group of lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Successful group of lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Number of subjects: 120
Study: 24056293

Group type: EXPERIMENTAL
Intervention: AT substitution in children with AT activity below 0.55 kIU/l (n = 36)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No AT substitution (n = 39)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Historical control without AT substitution (n = 10)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Prolonged continuous ASP treatment
Number of subjects: 85
Study: 21412424

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for 18 months
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 19110158

Group type: EXPERIMENTAL
Intervention: Ulcer depth greater than 3 mm
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: C-reactive protein greater than 3.2 mg/dL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination of ulcer depth and C-reactive protein
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ulcer depth greater than 3 mm or C-reactive protein greater than 3.2 mg/dL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ulcer depth greater than 3 mm or erythrocyte sedimentation rate greater than 60 mm/h
Number of subjects: 54
Study: 17227995

Group type: EXPERIMENTAL
Intervention: Regimen-DI (intensified treatment with six 2-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Number of subjects: 497

Group type: COMPARATOR
Intervention: Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Regimen-DI
Number of subjects: 497
Study: 15172271

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 108
Study: 11829390

Group type: EXPERIMENTAL
Intervention: Bio‐Oss (BO) with Bio‐Gide (BG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Open‐flap debridement (OFD)
Number of subjects: 21
Study: 9736420

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (enoxaparin, 1.5 mg/kg/day) subcutaneously (sc) once daily for 72 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (initial infusion rate 450 IU/kg/day) continuous intravenous (iv) for 72 hours
Number of subjects: 18
Study: 7914888

Group type: EXPERIMENTAL
Intervention: +2 Gz
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: +3 Gz
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: +4 Gz
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: +5 Gz
Number of subjects: 9
Study: 2690927

Group type: EXPERIMENTAL
Intervention: isovolaemic haemodilution
Number of subjects: 25

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 25